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CONDENSATION 1 
2 
Participants who reported moderately heavy or heavy baseline menstrual bleeding prior to 3 
initiation of copper intrauterine device were not at increased risk for method discontinuation. 4 
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3 
ABSTRACT 1 
Background: Heavy menstrual bleeding is a leading cause of copper intrauterine device (IUD) 2 
discontinuation. Thus, women with heavy baseline menstrual bleeding may be at increased risk 3 
for early copper IUD discontinuation. Our objective was to assess if there was an association 4 
between baseline menstrual bleeding pattern prior to IUD insertion and discontinuation rate at 12 5 
months among study participants who chose copper IUD at baseline. 6 
Study Design: We performed a secondary analysis of the Contraceptive CHOICE Project, a 7 
prospective observational cohort study of 9,256 women offered no cost contraception for 2-3 8 
years. Included in our study were participants who chose copper IUD for contraception and for 9 
whom method continuation data at 12 months were available. Prior to contraception initiation, 10 
participants were asked to qualify their menstrual bleeding over the past year as: light, moderate, 11 
moderately heavy or heavy. Light bleeding corresponded to using 10 or fewer pads/tampons per 12 
period. Moderate, moderately heavy and heavy bleeding corresponded to 11-20 pads/tampons, 13 
21-30 pads/tampons, and more than 30 pads/tampons per period, respectively. Subjects were 14 
then categorized into either a “heavy” baseline group (those reporting moderately heavy or heavy 15 
bleeding at baseline), or a “not heavy” group (those reporting light or moderate bleeding).  The 16 
12-month continuation rate for each group was then calculated using Kaplan-Meier survival 17 
function, and hazard ratio for risk of discontinuation was evaluated using a Cox proportional 18 
hazard model to determine if moderately heavy or heavy bleeding at baseline was associated 19 
with early discontinuation. 20 
Results: Of the 918 women meeting the inclusion criteria for this analysis, 165 were in the 21 
heavy baseline bleeding group, while 753 were in the not heavy bleeding group. The 12-month 22 
continuation rates for groups were similar: 80.2% (heavy) and 85.0% (not heavy; P=0.24). 23 
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4 
Patients reporting either moderately heavy or heavy baseline bleeding were not at increased risk 1 
for early discontinuation of copper IUD (hazard ratio 1.21, 95% CI 0.88, 1.66).  Our sample size 2 
provided greater than 90% power to detect a clinically important difference of 15% (assuming 3 
20% discontinuation rate in not heavy bleeding group and a 35% discontinuation rate in the 4 
heavy bleeding group). 5 
Conclusions: We did not find that women who reported baseline moderately heavy or heavy 6 
menstrual bleeding were at increased risk for early discontinuation. Thus, we do not believe that 7 
women with heavy menstrual bleeding should be discouraged from using this safe and highly-8 
effective form of contraception. 9 
 10 
Key words: Heavy menstrual bleeding, copper intrauterine device, discontinuation 11 
 12 
  13 
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INTRODUCTION 1 
Recent reports have documented significant declines in teen pregnancy and abortions in 2 
the US.1,2 One proposed explanation for this decrease is the increased use of the most effective 3 
methods of contraception: long-acting reversible contraception or LARC.3 Intrauterine devices 4 
(IUDs) constitute the predominant form of LARC, with an estimated 4.4 million users (10.4% of 5 
total contraceptive use) in the US.4 These devices demonstrate low failure rates in tandem with 6 
high continuation rates. The copper IUD, for example, has a first-year unintended pregnancy rate 7 
of 0.8% with 12-month and 24-month continuation rates of 85% and 77%, respectively.5,6 IUDs 8 
are cost-effective as well. One analysis found that, over a 5-year period, the cost-effectiveness of 9 
IUDs and vasectomy were similar when taking into account both method cost and the cost of 10 
unintended pregnancy.5  11 
The copper IUD was originally introduced in the 1970s.  This device has a long history of 12 
being both safe and effective.7 In addition to its low failure rate, the copper IUD offers a 13 
hormone-free, reversible contraceptive option, and is currently approved for up to 10 years of use 14 
in the US. However, heavy menstrual bleeding is one of the most common side effects of the 15 
copper IUD resulting in device removal.8 The objective of this study was to evaluate if there was 16 
an association between baseline heavy menstrual bleeding and early copper IUD removal. Our 17 
hypothesis was that women with a pattern of heavy menses prior to insertion were more likely to 18 
discontinue a copper IUD within 12 months. 19 
  20 
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6 
MATERIALS & METHODS 1 
We performed a secondary analysis of the Contraceptive CHOICE Project to evaluate the 2 
effect of baseline menstrual bleeding on copper IUD continuation. CHOICE was a prospective 3 
observational cohort study conducted between 2007 and 2013.  The Project offered 2-3 years of 4 
contraception at no cost to participants in an attempt to promote use of the most effective 5 
methods of contraception to reduce unintended pregnancies in the St. Louis region. All FDA-6 
approved methods of reversible contraception were offered to study participants.  Methods were 7 
introduced in order of effectiveness; LARC methods (implant, IUD) were introduced first.   8 
Eligible females were between the ages of 14-45, sexually active with a male partner (or 9 
soon to be), and currently either not using any form of contraception or willing to initiate a new 10 
form of reversible contraception. Participants were recruited from a variety of settings (e.g. 11 
abortion clinics, university-based research clinics, ambulatory clinics, etc.) and included 12 
students, women of all income and socioeconomic strata, post-abortion and postpartum patients, 13 
and friends and acquaintances of participants.  14 
Study participants underwent an initial in-person interview to collect baseline 15 
demographic, reproductive, and medical data. Participants were asked questions pertaining to 16 
menstrual history as part of the baseline survey. Subjects were asked to categorize their baseline 17 
menstrual bleeding as light (using 10 or fewer pads/tampons per period), moderate (11-20 18 
pads/tampons), moderately heavy (21-30 pads/tampons), heavy (more than 30 pads/tampons), or 19 
too variable or irregular to say. These responses provided the foundation for our analysis. Of 20 
note, only two women (0.2% of participants choosing copper IUD) reported bleeding as too 21 
variable or too irregular to describe. These participants were therefore excluded from our 22 
analysis.  23 
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7 
Our analysis focused on the association of baseline bleeding pattern on copper IUD 1 
discontinuation. Method continuation was monitored by periodic telephone surveys at 3 and 6 2 
months following method initiation, and then for every 6 months of participation in the project. 3 
The primary outcome of our study was discontinuation at 12 months from the time of initiation. 4 
Women who chose copper IUD at enrollment and had method use data to determine continuation 5 
status by 12 months survey were included in this analysis.   6 
Prior to statistical analysis, we evaluated the distribution of baseline bleeding patterns.   7 
Due to the small number of participants citing heavy baseline bleeding, we combined the 8 
moderately heavy and heavy bleeding groups into our “heavy” baseline bleeding group, and 9 
included the light and moderate bleeding groups into the “not heavy group.” Means and standard 10 
deviations, or frequencies and percentages were used to describe demographic characteristics of 11 
participants based on the data type, and chi-square test or t-test were used to compare the 12 
participants characteristics between group 1 and group 2 participants. A survival analysis 13 
approach was applied where the outcome event was defined as copper IUD discontinuation, and 14 
time to event was defined as the time period from method initiation to the time point when the 15 
participant discontinued copper IUD.  16 
If the participant was lost to follow-up, she was censored at her last time of contact. 17 
Participants were censored if the contraceptive method was discontinued to attempt pregnancy.  18 
The Kaplan-Meier survival curve was calculated and was used to estimate the 12-month 19 
continuation/discontinuation rates. A Cox proportional hazard model was used to estimate the 20 
association between baseline bleeding and pattern 12-month discontinuation. We considered a 21 
covariate a confounder if it changed the effect estimate by 10% or more when the covariate was 22 
added to the model. Effect modification was assessed by evaluating the significance of the 23 
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interaction term between the covariate and bleeding pattern in the model. A P-value of less than 1 
0.05 was considered statistically significant.  Stata software (version 11, StataCorp, College 2 
station, Texas) was used for all analyses. 3 
Since this was a secondary analysis of an existing dataset, we did not do an a prior 4 
power/sample size analysis.  However, our post hoc power analysis revealed a greater than 90% 5 
power to detect a clinically important difference of 15% (assuming 20% discontinuation rate in 6 
not heavy bleeding group and a 35% discontinuation rate in the heavy bleeding group) based on 7 
our sample size. 8 
  9 
RESULTS 10 
A total of 1102 study participants initially chose a copper IUD for contraception, 918 11 
(83.3%) of which initiated copper IUD by 3 months survey and had continuation data available 12 
at 12 months. Of these 918 subjects, 165 reported either moderately heavy (n=141) or heavy 13 
(n=24) bleeding prior to IUD insertion, and thus constituted the heavy baseline bleeding group. 14 
The remaining 753 copper IUD users reported either light (n=192) or moderate (n=561) baseline 15 
bleeding and therefore were placed in the not heavy group (see Figure 1, Flow Diagram). 16 
The baseline demographic and reproductive characteristics of our sample of copper IUD 17 
users stratified by baseline bleeding pattern are provided in the Table.  Subjects in the heavy 18 
bleeding group were more likely to be obese and to have a history of a sexually transmitted 19 
infection (STI) than participants in the not heavy group.  There were no significant differences in 20 
age, race, education, marital status, socioeconomic status, insurance, or other baseline 21 
characteristics when we compared the two groups. 22 
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 At 12 months from the time of copper IUD initiation, participants in the heavy and the 1 
not heavy baseline bleeding groups had similar continuation rates: 80.2% and 85.0%, 2 
respectively (P=0.24; Figure 2). Patients in the heavy bleeding group  were not at increased risk 3 
for early discontinuation (hazard ratio 1.21, 95% CI 0.88, 1.66). None of the participant variables 4 
listed in the Table were determined to be confounders or effect modifiers; therefore, a 5 
multivariable analysis was not performed.  6 
 7 
COMMENT 8 
The goal of our study was to assess if women with baseline heavy menstrual bleeding 9 
were more likely to discontinue copper IUD at one year as compared to women without heavy 10 
bleeding. Our analysis, however, did not show a significant relationship between baseline heavy 11 
menstrual bleeding and discontinuation of copper IUD at one year. This was somewhat 12 
surprising because, as previously mentioned, heavy bleeding is one of the most common side 13 
effects cited for early copper IUD discontinuation.8,9  14 
Of note, our hypothesis was that women with heavy baseline bleeding would be at 15 
increased risk of copper IUD discontinuation. This was based on the premise that any further 16 
bleeding caused by the device would prompt its removal. It is possible, however, that individuals 17 
with heavy baseline bleeding could be more tolerant of the bleeding associated with copper IUD, 18 
and therefore less likely to discontinue use of this device. 19 
We attempted to compare the results of our study with existing data pertaining to the 20 
relationship between baseline menstrual bleeding and copper IUD discontinuation. We found 21 
only one relevant study in our search of the existing literature. Zhang examined the effect of 22 
various patient characteristics on copper IUD discontinuation, of which baseline bleeding was 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Revised Draft: 12 Aug 2018 
 
 
10
included.10 Although not formally discussed in the report, menstrual flow prior to IUD insertion 1 
(i.e. ‘usual’ versus ‘more than usual’) can be found in the table of patient characteristics. The 2 
tabulated crude odds ratio (OR 1.1, 95% CI 0.5, 2.2) did not indicate a significant relationship 3 
between bleeding and discontinuation10. However, the study was also likely under-powered to 4 
evaluate this relationship given the low number of women reporting heavy baseline bleeding. 5 
Additional studies were identified which examined patient characteristics and personal 6 
reasons associated with copper IUD discontinuation, however baseline menstrual bleeding was 7 
not among the factors evaluated.11,12 Stanback and Grimes did examine the effect of bleeding on 8 
copper IUD discontinuation; however, in their study the assessment of bleeding occurred one 9 
month after IUD insertion.13 Therefore, this study did not provide a direct comparison for our 10 
analysis, which sought to investigate the relationship of bleeding prior to insertion. 11 
One strength of our study is a reasonably large sample size of copper IUD users from a 12 
prospective cohort study of a diverse sample of participants. Data were generated using a 13 
standardized patient survey, and longitudinal follow-up included assessment of method 14 
discontinuation supplemented with medical record review. Less than 20% of copper IUD users 15 
were lost to follow up at 12 months.  16 
Despite the overall large number of CHOICE subjects selecting copper IUD, the greatest 17 
limitation of our analysis was the small number of participants reporting heavy baseline bleeding 18 
(n=24). We did, however, have over 140 participants who stated their baseline bleeding pattern 19 
was moderately heavy.  It is possible the low number of participants in the heavy bleeding 20 
category was the result of either patients or providers choosing not to use copper IUD in the 21 
setting of reported heavy baseline bleeding, given the concern for increased bleeding and 22 
subsequent early discontinuation. This low number of heavy bleeders limited our power to assess 23 
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copper IUD continuation rates based upon the original four categories of bleeding. Thus, the 1 
power of our study to assess this group is limited, and there is a possibility of a type II error. 2 
While our dataset was considered a strength of this study, the subjective nature of the 3 
data itself (i.e. self-reported bleeding) could also be perceived as a limitation. Patient-reported 4 
menstrual bleeding patterns have long been shown to correlate poorly with objective measures of 5 
menorrhagia14. Reporting of pad or tampon usage (which defined each of the original subgroups) 6 
is also likely prone to recall bias. Further, variability likely exists with regards to how often 7 
pads/tampons are replaced, or to what degree products are soiled prior to changing. Despite these 8 
limitations, we must keep in mind that it is the patient’s perception of heavy bleeding that can 9 
both influence contraceptive counseling and thus limit the use of the copper IUD. 10 
Copper IUDs are safe, highly effective, and have a long and successful track record7. In 11 
addition to providing a non-hormonal option for contraception, the copper IUD also has the 12 
longest duration of use of all forms of reversible contraception. Further, some women hold a 13 
desire to maintain monthly menses. Morrison et al. reported that the majority of women (83%) in 14 
their survey viewed menstruation as natural, while only 32% viewed it as a “curse”.15 15 
Unfortunately, IUD use in general is significantly lower in the US when compared to 16 
many other countries. IUDs – mostly copper – comprise an estimated 22.8% of contraceptive 17 
methods used worldwide, and yet only 6.1% in the US16. Much of this discord likely stems from 18 
counseling provided by medical providers. For example, Dehlendorf et al. found that, during 19 
contraception counseling visits, providers were least likely to recommend the copper IUD17. 20 
Another study concluded that providers do not routinely prepare patients interested in copper 21 
IUD for the possibility of increased menstrual bleeding, thereby setting the stage for 22 
dissatisfaction with the device18. There also seems a paucity of guidance in managing increased 23 
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bleeding associated with the initiation of a copper IUD, which has been shown to both diminish 1 
with time and be responsive to medical therapy19.  2 
In summary, the copper IUDs is a safe and highly-effective method of contraception. 3 
Many clinicians may have a bias against copper IUD use due to concerns for increased bleeding, 4 
especially in women with pre-existing heavy menses. Our analysis, however, did not 5 
demonstrate a correlation between early copper IUD discontinuation and heavy baseline 6 
menstrual bleeding. Incorporating this information, along with the other proven benefits of 7 
LARC, into contraceptive counseling may improve utilization rates of the copper IUD. 8 
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Table: Baseline Characteristics of Copper IUD Users by Baseline Bleeding Pattern 1 
 2 
 Heavy  
Baseline Bleeding  
Group 
 (n=165) 
Not Heavy 
Baseline Bleding 
Group 
 (n=753) 
 
 
 
P-value 
Age 28.5 ± 6.1 27.6 ± 6.3 0.13 
Race    0.79 
African American 58 (35.2) 272 (36.1)  
White 94 (57.0) 411 (54.6)  
Others 13 (7.9) 70 (9.3)  
Education     0.83 
High school diploma or less 45 (27.3) 188 (25.0)  
Some college 68 (41.2) 320 (42.5)  
College degree or graduate school 
 
52 (31.5) 245 (32.5)  
Income     0.84 
None 26 (15.9) 135 (18.2)  
$1-800 47 (28.7) 207 (27.9)  
$801-1,600 45 (27.4) 210 (28.3)  
$1,601 or more 46 (28.0) 189 (25.5)  
Body mass index    0.01 
Underweight 2 (1.2) 19 (2.6)  
Normal 67 (40.9) 324 (43.5)  
Overweight 29 (17.7) 192 (25.8)  
Obese 66 (40.2) 210 (28.2)  
Low socioeconomic status     0.14 
No 63 (38.2) 335 (44.5)  
Yes 102 (61.8) 417 (55.5)  
Insurance    0.81 
None 67 (41.1) 301 (40.1)  
Private 80 (49.1) 363 (48.3)  
Public 16 (9.8) 87 (11.6)  
Gravidity    0.22 
0 40 (24.2) 221 (29.3)  
1 32 (19.4) 108 (14.3)  
2 25 (15.2) 135 (17.9)  
3 or higher 68 (41.2) 289 (38.4)  
Parity    0.16 
0 65 (39.4) 334 (44.4)  
1 30 (18.2) 162 (21.5)  
2 36 (21.8) 149 (19.8)  
3 or higher 34 (20.6) 108 (14.3)  
Unintended pregnancies    0.41 
0 50 (30.3) 261 (34.7)  
1 43 (26.1) 154 (20.5)  
2 29 (17.6) 142 (18.9)  
3 or higher 43 (26.1) 195 (25.9)  
History of abortion    0.80 
No 98 (59.4) 439 (58.3)  
Yes 67 (40.6) 314 (41.7)  
History of STI    0.04 
No 87 (52.7) 463 (61.6)  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Revised Draft: 12 Aug 2018 
 
 
17
Yes 78 (47.3) 289 (38.4)  
Any current STI    0.81 
No 157 (95.2) 715 (95.6)  
Yes 8 (4.8) 33 (4.4)  
 1 
STI, sexually transmitted infection. 2 
Data are mean ± standard deviation or n (%) unless otherwise specified. 3 
 4 
  5 
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Figure 1: Flow diagram and distribution of baseline bleeding patterns of CHOICE participants 1 
using the copper IUD 2 
 3 
Figure 2:  Kaplan-Meier survival curves comparing copper IUD continuation stratified by 4 
baseline bleeding status (not heavy = light or moderate bleeding; heavy = moderately heavy or 5 
heavy bleeding). 6 
 7 
 8 
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